FDA New, GMP Do
Clinical Phase II, III Intermediates
GMP Custom synthesis, Full Document
R&D Center: 8000 sq, More than 100 hoods
Pilot Plant: 20000sq, 40 reactors from 5-200L
Manufacturing Site: 800000sq, 40 reactors from 100-5000L
Web: www.eosmedchem.com
This is my R&D youtube: https://youtu.be/r5cJdXKNXHk
| Opaviraline, 178040-94-3, Opaviraline Intermediate 446-35-5, stock 443.8g, white powder, assay by HPLC 98.2%, HNMR, LCMS we supply. |
| Opaviraline, 178040-94-3, Opaviraline Intermediate 1492-24-6, stock 489.6g, white powder, assay by HPLC 99.2%, HNMR, LCMS we supply. |
| Opaviraline, 178040-94-3, Opaviraline Intermediate 479677-30-0, stock 642g, white powder, assay by HPLC 98.4%, HNMR, LCMS we supply. |
| Opaviraline, 178040-94-3, Opaviraline Intermediate 178041-67-3, stock 489.9g, white powder, assay by HPLC 99.4%, HNMR, LCMS we supply. |
| Opaviraline, 178040-94-3, Opaviraline Intermediate 108-23-6, stock 296g, white powder, assay by HPLC 98.5%, HNMR, LCMS we supply. |
| Opaviraline, 178040-94-3, Opaviraline Intermediate 178040-94-3, stock 933.1g, white powder, assay by HPLC 98.6%, HNMR, LCMS we supply. |
